A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, and effect on quality of life of oral
ibandronate (Bondronat) in participants with breast cancer and metastatic bone disease. The
anticipated time on study treatment is 25 weeks, and the target sample size is 50
individuals.